Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell1, Ines Pires da Silva2,3,4,5, Peter A. Johansson1, Alexander M. Menzies2,4,6,7, James S. Wilmott2,3,4, Venkateswar Addala1,8, Matteo S. Carlino2,4,9,10, Helen Rizos11, Katia Nones1, Jarem J. Edwards2,3,4, Vanessa Lakis1, Stephen H. Kazakoff1, Pamela Mukhopadhyay1, Peter M. Ferguson2,4,12, Conrad Leonard1, Lambros T. Koufariotis1, Scott Wood1, Christian U. Blank13,14, John F. Thompson2,4,7,15, Andrew J. Spillane2,4,7
1QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
2Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia
3Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006, Australia
4Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia
5Cancer Centre, Blacktown Hospital, Sydney, NSW 2148, Australia
6Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia
7Mater Hospital, Sydney, NSW 2060, Australia
8Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia
9Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia
10Department of Medical Oncology, Westmead Hospital, Sydney, NSW 2145, Australia
11Faculty of Medicine Health and Human Sciences, Macquarie University, North Ryde, NSW, 2109, Australia
12Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW 2050, Australia
13Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
14Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia